Time to viral load suppression with 8-week versus 12-week ravidasvir/sofosbuvir regimens among chronic hepatitis C patients in Malaysia: a non-inferiority, randomized clinical trial
BMC Infectious Diseases·
- DOI
- 10.1186/s12879-026-13741-5
- PMID
- 42277657
- PMCID
- —
- OpenAlex
- W7164404407
- Study type
- Randomised controlled trial
- Publisher
- Springer Science and Business Media LLC
- Article type
- journal-article
- Integrity
- current
Why this research matters now
The findings provide treatment-duration evidence from Malaysian adults with chronic hepatitis C and may inform further evaluation of shorter ravidasvir/sofosbuvir regimens. The abstract does not establish programmatic recommendations, population-level effectiveness, or effects on transmission or mortality.
Structured evidence summary
Research question
The study examined whether time to HCV RNA viral-load suppression differed between 8-week and 12-week ravidasvir/sofosbuvir regimens in adults with chronic hepatitis C in Malaysia, and assessed factors related to suppression time.
Study design
This was a secondary analysis of data from a randomized, open-label, multicenter, non-inferiority clinical trial conducted from 2016 to 2020. Kaplan-Meier analysis and Cox proportional hazards regression were used.
Population and setting
The analysis included 321 adults with chronic HCV infection treated in Malaysia. The supplied abstract refers to patients with multiple HCV genotypes, including a predominant Genotype 3 population and a Genotype 1 subgroup.
Main findings
Median time to viral-load suppression was 28 days in both treatment groups, with no statistically significant difference in the Kaplan-Meier analysis. Adjusted regression estimated a higher likelihood of earlier suppression with the 8-week regimen, while higher baseline HCV RNA was associated with delayed suppression. The abstract also reports a treatment-by-genotype interaction and cautions that the shorter regimen's apparent benefit, particularly in the predominant Genotype 3 population, needs further investigation.
Public-health relevance
The findings provide treatment-duration evidence from Malaysian adults with chronic hepatitis C and may inform further evaluation of shorter ravidasvir/sofosbuvir regimens. The abstract does not establish programmatic recommendations, population-level effectiveness, or effects on transmission or mortality.
Important limitations
The abstract identifies modest statistical power and advises caution in interpreting the shorter regimen's association with earlier suppression. It also reports that genotype-specific differences, especially in Genotype 3, require further study before broad recommendations. This summary is additionally limited to the supplied single-article abstract and metadata; the original paper is required for decision-grade interpretation.
GIDS interpretation
The article is discoverable as Malaysian chronic hepatitis C treatment evidence concerning ravidasvir/sofosbuvir duration and viral-load suppression. The supplied material does not connect these findings to a live surveillance signal or confirm surveillance data.
Related GIDS surveillance
Literature context does not validate, explain, or change a surveillance signal. Exact and contextual relationships are shown separately.
Evidence relationships
This article has 9 auditable classifier relationships to diseases, places, topics, and study design.